<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00088933</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00049</org_study_id>
    <secondary_id>NCI-2009-00049</secondary_id>
    <secondary_id>CDR0000377574</secondary_id>
    <secondary_id>02-452</secondary_id>
    <secondary_id>02-452</secondary_id>
    <secondary_id>6230</secondary_id>
    <secondary_id>R01CA088972</secondary_id>
    <secondary_id>P30CA051008</secondary_id>
    <nct_id>NCT00088933</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer</brief_title>
  <official_title>Randomized Single Institution Pilot Study of Vaccinia-CEA(6D)-TRICOM and Fowlpox-CEA(6D)-TRICOM With GM-CSF in Combination With Docetaxel in Patients With CEA-Bearing Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This randomized phase I trial studies the side effects, best way to give, and best dose of&#xD;
      docetaxel when given together with vaccine therapy and sargramostim in treating patients with&#xD;
      metastatic lung cancer or metastatic colorectal cancer. Vaccines may make the body build an&#xD;
      immune response to kill tumor cells. Colony-stimulating factors such as sargramostim increase&#xD;
      the number of immune cells found in bone marrow and peripheral blood. Drugs used in&#xD;
      chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining vaccine therapy and sargramostim with docetaxel may kill&#xD;
      more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the recommended dose and schedule of docetaxel when given in combination with&#xD;
      recombinant vaccinia-CEA-TRICOM vaccine, recombinant fowlpox-CEA-TRICOM vaccine, and&#xD;
      sargramostim (GM-CSF), defined by best immune response with acceptable toxicity, in patients&#xD;
      with carcinoembryonic antigen (CEA)-expressing metastatic lung or colorectal cancer.&#xD;
&#xD;
      II. Compare the effect of varying doses and schedules of docetaxel on CEA-specific T-cell&#xD;
      immune responses by ELISPOT assay in patients treated with these regimens.&#xD;
&#xD;
      III. Compare objective antitumor response in patients treated with these regimens.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      This is a 2-part, randomized, pilot study. Patients are randomized to 1 of 6 treatment arms:&#xD;
      arms I, II, and III in part I (lung cancer and colorectal cancer patients) and arms IV, V,&#xD;
      and VI in part II (lung cancer patients only). Patients are stratified according to disease&#xD;
      site and HLA-A2 positivity (positive vs negative). At least 6 of 10 patients must be HLA-A2&#xD;
      positive for each of the treatment arms.&#xD;
&#xD;
      Vaccinia-CEA-TRICOM vaccine (parts I and II): In all treatment arms, patients receive&#xD;
      vaccinia-CEA-TRICOM vaccine intradermally on day 1 and sargramostim (GM-CSF) subcutaneously&#xD;
      (SC) into the vaccine site on days 1-4.&#xD;
&#xD;
      Fowlpox-CEA-TRICOM vaccine and concurrent chemotherapy:&#xD;
&#xD;
      Part I (lung cancer and colorectal cancer patients):&#xD;
&#xD;
      ARM 1: Three weeks after treatment with vaccinia-CEA-TRICOM vaccine, patients receive&#xD;
      fowlpox-CEA-TRICOM vaccine SC on day 1 and GM-CSF SC into each vaccination site on days 1-4.&#xD;
&#xD;
      ARM II: Patients receive fowlpox-CEA-TRICOM vaccine and GM-CSF as in arm I and lower-dose&#xD;
      docetaxel IV over 30 minutes on days 1 and 8.&#xD;
&#xD;
      ARM III: Patients receive fowlpox-CEA-TRICOM vaccine and GM-CSF as in arm I and standard-dose&#xD;
      docetaxel IV over 30 minutes on days 1 and 8.&#xD;
&#xD;
      Part II (lung cancer patients only):&#xD;
&#xD;
      ARM IV: Patients receive fowlpox-CEA-TRICOM vaccine and GM-CSF as in arm I and full-dose&#xD;
      docetaxel IV over 1 hour on day 1.&#xD;
&#xD;
      ARM V: Patients receive full-dose docetaxel IV over 1 hour on day 1, fowlpox-CEA-TRICOM&#xD;
      vaccine SC on day 8, and GM-CSF SC into each vaccination site on days 8-11.&#xD;
&#xD;
      ARM VI: Patients receive full-dose docetaxel as in arm V, fowlpox-CEA-TRICOM vaccine SC on&#xD;
      day 15, and GM-CSF SC into each vaccination site on days 15-18.&#xD;
&#xD;
      Treatment in all arms repeats every 21 days for a total of 4 courses in the absence of&#xD;
      disease progression or unacceptable toxicity. Patients who do not have significant disease&#xD;
      progression or unacceptable toxicity after 4 courses of treatment may receive additional&#xD;
      fowlpox-CEA-TRICOM vaccine and docetaxel according to the treatment arm on which they were&#xD;
      enrolled at study entry. Patients are followed every 6 months for 2 years and then annually&#xD;
      for 13 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>June 2004</start_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-tumor response rate defined as the number of patients in each arm achieving a complete or partial response or stable disease divided by the total number of patients on each arm measured according to standard RECIST guidelines</measure>
    <time_frame>Up to 6 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune response defined as the numbers of patients who achieve an ELISPOT result of 1/30,000 or higher divided by the number of HLA-A2 positive individuals for each treatment arm</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>The actual ELISPOT will be recorded for each individual and will be presented graphically.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients experiencing each of the toxicities by grade for each treatment arm</measure>
    <time_frame>Up to 6 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average quantity of circulating CEA cells determined by quantitative real time RT-PCR</measure>
    <time_frame>Up to 6 years</time_frame>
    <description>The impact of the combination therapy on CCC will be presented graphically with descriptive statistics. Will be plotted for each time point by each treatment group.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Extensive Stage Small Cell Lung Cancer</condition>
  <condition>Recurrent Colon Cancer</condition>
  <condition>Recurrent Non-small Cell Lung Cancer</condition>
  <condition>Recurrent Rectal Cancer</condition>
  <condition>Recurrent Small Cell Lung Cancer</condition>
  <condition>Stage IV Colon Cancer</condition>
  <condition>Stage IV Non-small Cell Lung Cancer</condition>
  <condition>Stage IV Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three weeks after treatment with vaccinia-CEA-TRICOM vaccine, patients receive fowlpox-CEA-TRICOM vaccine SC on day 1 and GM-CSF SC into each vaccination site on days 1-4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive fowlpox-CEA-TRICOM vaccine and GM-CSF as in arm I and lower-dose docetaxel IV over 30 minutes on days 1 and 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive fowlpox-CEA-TRICOM vaccine and GM-CSF as in arm I and standard-dose docetaxel IV over 30 minutes on days 1 and 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive fowlpox-CEA-TRICOM vaccine and GM-CSF as in arm I and full-dose docetaxel IV over 1 hour on day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive full-dose docetaxel IV over 1 hour on day 1, fowlpox-CEA-TRICOM vaccine SC on day 8, and GM-CSF SC into each vaccination site on days 8-11.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm VI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive full-dose docetaxel as in arm V, fowlpox-CEA-TRICOM vaccine SC on day 15, and GM-CSF SC into each vaccination site on days 15-18.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant fowlpox-CEA(6D)/TRICOM vaccine</intervention_name>
    <description>Given intradermally</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_label>Arm IV</arm_group_label>
    <arm_group_label>Arm V</arm_group_label>
    <arm_group_label>Arm VI</arm_group_label>
    <other_name>fowlpox-CEA-B7-1/ICAM-1/LFA-3</other_name>
    <other_name>rF-CEA(6D)TRICOM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant vaccinia-CEA(6D)-TRICOM vaccine</intervention_name>
    <description>Given intradermally</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_label>Arm IV</arm_group_label>
    <arm_group_label>Arm V</arm_group_label>
    <arm_group_label>Arm VI</arm_group_label>
    <other_name>rV-CEA(6D)-TRICOM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_label>Arm IV</arm_group_label>
    <arm_group_label>Arm V</arm_group_label>
    <arm_group_label>Arm VI</arm_group_label>
    <other_name>RP 56976</other_name>
    <other_name>Taxotere</other_name>
    <other_name>TXT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sargramostim</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_label>Arm IV</arm_group_label>
    <arm_group_label>Arm V</arm_group_label>
    <arm_group_label>Arm VI</arm_group_label>
    <other_name>GM-CSF</other_name>
    <other_name>Leukine</other_name>
    <other_name>Prokine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed lung OR colorectal cancer&#xD;
&#xD;
          -  Incurable metastatic disease&#xD;
&#xD;
          -  Currently available standard treatment not likely to offer a survival advantage or&#xD;
             result in superior palliation&#xD;
&#xD;
          -  Evaluable disease by radiograph&#xD;
&#xD;
          -  Tumor must currently express carcinoembryonic antigen (CEA) by immunohistochemistry OR&#xD;
             CEA &gt;= 10 ng/mL at any point during disease course&#xD;
&#xD;
          -  No clinically active brain metastases&#xD;
&#xD;
          -  Must have had first- and second-line treatment OR declined second-line treatment (part&#xD;
             I only)&#xD;
&#xD;
          -  Patients with colon cancer must have had or have been offered treatment with&#xD;
             oxaliplatin (part I only)&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
          -  Life expectancy of at least 4 months&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/mm^3&#xD;
&#xD;
          -  WBC &gt;= 3,000/mm^3&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  SGOT and SGPT =&lt; 2.5 times upper limit of normal (ULN) AND alkaline phosphatase&#xD;
                  normal&#xD;
&#xD;
               -  SGOT and SGPT =&lt; normal AND alkaline phosphatase =&lt;4.0 times ULN&#xD;
&#xD;
          -  Hepatitis B and C negative by clinical history and physical exam&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 mg/dL OR creatinine clearance &gt;= 60 mL/min&#xD;
&#xD;
          -  Proteinuria =&lt; grade 1&#xD;
&#xD;
          -  No known or suspected history of impaired cardiac function as evidenced by baseline&#xD;
             echocardiogram&#xD;
&#xD;
          -  Adequate pulmonary function&#xD;
&#xD;
          -  No history or clinical evidence of immune deficiency or autoimmunity&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No history of or concurrent diagnosis of any of the following:&#xD;
&#xD;
               -  Altered immunodeficiency&#xD;
&#xD;
               -  Eczema or other eczematoid skin disorders&#xD;
&#xD;
               -  Acute, chronic, or exfoliative skin condition (e.g., atopic dermatitis, burns,&#xD;
                  impetigo, varicella zoster, severe acne, or other open rashes or wounds)&#xD;
&#xD;
          -  No history of allergy or untoward reaction to prior vaccination with vaccinia virus&#xD;
&#xD;
          -  No history of severe hypersensitivity reaction to docetaxel or other drugs formulated&#xD;
             with polysorbate 80&#xD;
&#xD;
          -  No history of allergy to eggs or egg products&#xD;
&#xD;
          -  No frequent vomiting or severe anorexia&#xD;
&#xD;
          -  No inflammatory bowel disease&#xD;
&#xD;
          -  No Crohn's disease&#xD;
&#xD;
          -  No ulcerative colitis&#xD;
&#xD;
          -  No active diverticulitis&#xD;
&#xD;
          -  Neuropathy =&lt; grade 1 (sensory neuropathy)&#xD;
&#xD;
          -  No uncontrolled seizure disorder&#xD;
&#xD;
          -  No encephalitis&#xD;
&#xD;
          -  No multiple sclerosis&#xD;
&#xD;
          -  Must be maintaining a reasonable state of nutrition (=&lt; 10 % weight loss in the past&#xD;
             month)&#xD;
&#xD;
          -  Must be able to avoid close household contact (defined as sharing housing or having&#xD;
             close physical contact) for at least 3 weeks after recombinant vaccinia vaccination&#xD;
             with individuals with active or a history of eczema or other eczematoid skin disorders&#xD;
&#xD;
          -  Must be able to avoid close household contact (defined as sharing housing or having&#xD;
             close physical contact) for at least 3 weeks after recombinant vaccinia vaccination&#xD;
             with those with unresolved acute, chronic, or exfoliative skin conditions (e.g.,&#xD;
             atopic dermatitis, burns, impetigo, varicella zoster, severe acne, or other open&#xD;
             rashes or wounds)&#xD;
&#xD;
          -  Must be able to avoid close household contact (defined as sharing housing or having&#xD;
             close physical contact) for at least 3 weeks after recombinant vaccinia vaccination&#xD;
             with any of the following individuals: pregnant or nursing women; children =&lt; 5 years&#xD;
             of age; immunodeficient or immunosuppressed individuals (by disease or therapy),&#xD;
             including HIV infection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 6 months&#xD;
             after study participation&#xD;
&#xD;
          -  No other concurrent serious medical illness that would preclude study participation&#xD;
&#xD;
          -  No concurrent biologic therapy&#xD;
&#xD;
          -  No other concurrent immunotherapy&#xD;
&#xD;
          -  At least 6 weeks since prior nitrosoureas or mitomycin&#xD;
&#xD;
          -  Prior docetaxel allowed (part I only)&#xD;
&#xD;
          -  No prior docetaxel (part II only)&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  No concurrent systemic steroids except for the following:&#xD;
&#xD;
               -  physiologic doses for systemic steroid replacement therapy&#xD;
&#xD;
               -  local (topical, nasal, or inhaled) steroid use&#xD;
&#xD;
               -  no concurrent steroid eye drops&#xD;
&#xD;
               -  premedication prior to and after docetaxel&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
          -  No prior radiotherapy to &gt; 50 % of all nodal groups&#xD;
&#xD;
          -  More than 21 days since prior major surgery&#xD;
&#xD;
          -  No prior splenectomy&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  At least 3-4 weeks since prior cytotoxic therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Marshall</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lombardi Comprehensive Cancer Center at Georgetown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lombardi Comprehensive Cancer Center at Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>August 4, 2004</study_first_submitted>
  <study_first_submitted_qc>August 4, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2004</study_first_posted>
  <last_update_submitted>March 28, 2014</last_update_submitted>
  <last_update_submitted_qc>March 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

